COMMUNIQUÉS West-GlobeNewswire

Apyx Medical Corporation Reports Third Quarter 2025 Financial Results
06/11/2025
Initiated full U.S. commercial launch of AYON Body Contouring System ™ (AYON) at end of Q3 2025, with demand for pre-orders exceeding expectations Submitted new 510(k) for AYON for device label expansion to include [...]
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
06/11/2025
Positive topline results announced from Phase 2a clinical trial of RAP-219 in patients with focal onset seizures Phase 2 trial of RAP-219 in bipolar mania enrolling patients and on track, with topline results expected [...]
Opus Genetics Announces $23 Million Registered Direct Offering
06/11/2025
- Financing led by Perceptive Advisors and Balyasny Asset Management - - Proceeds targeted to fund rapid development of ophthalmic gene therapy clinical programs - RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2025 (GLOBE [...]
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
06/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney [...]
Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance
06/11/2025
Third quarter performance driven by strong portfolio royalty revenue growth of 47% 2025 full year revenue guidance increased to $225 million - $235 million (previously $200 million - $225 million) and adjusted earnings [...]
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
06/11/2025
Baergic shareholders eligible to receive up to approximately $82 million in potential development, regulatory, and sales milestones plus a tiered mid-to-high single digit royalty on global net sales from Axsome MIAMI, [...]
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
06/11/2025
Announced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor, and expect to initiate Phase 1 study in first quarter of [...]
Accipiter Biosciences Emerges from Stealth with $12.7 Million in Seed Financing to Deliver de novo Protein Therapies for Complex Diseases
06/11/2025
Strong syndicate of investors co-led by Takeda and Flying Fish Partners Proceeds will advance preclinical programs in immunology and oncology Strategic partnerships established with Pfizer and Kite Pharma, a Gilead [...]
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
06/11/2025
Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABA A α2,3 receptor positive allosteric modulator Deepens Axsome’s broad and innovative neuroscience portfolio with a synergistic early-stage [...]
Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program
06/11/2025
One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner’s National Priority Voucher for E-cigarette or Vaping Cessation Conference Call Scheduled for 8:30 AM EST Today, November 6, 2025 SEATTLE and [...]
American Shared Hospital Services Announces Third Quarter Financial Results Conference Call
06/11/2025
Call Scheduled for November 13 th at 1:00 PM ET SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery [...]
TREOS Bio Announces Publication of Phase 1b Clinical Trial Results of PolyPEPI1018 Plus TAS-102 in Refractory MSS mCRC in JCO Oncology Advances
06/11/2025
First study to report promising activity for an active immunotherapy combined with TAS-102 (LONSURF®) in late-stage MSS mCRC; TREOS advances Phase II programme with Charité – Universitätsmedizin Berlin and Junshi [...]
ProQR Announces Third Quarter 2025 Operating and Financial Results
06/11/2025
Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseases Initiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability, and PK data [...]
Immunocore reports third quarter financial results and provides a business update
06/11/2025
Immunocore reports third quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $103.7 million in 3Q 2025, growing by 29% year-over-year Phase 3 TEBE-AM trial on track to [...]
Interim Report Q3 2025: Solid quarter with 1% organic growth, 11% EBITA margin and DKK 410 million cash flow
06/11/2025
Highlights The Hearing division delivered 7% organic revenue growth driven by the continued strong performance of ReSound Vivia, enabling broad-based market share gains. The divisional profit margin ended at 34%, driven [...]
8% organic sales growth after first nine months. Full-year organic sales growth narrowed upwards.
06/11/2025
Ester Baiget, President & CEO: ” I am pleased with our performance in the first nine months, where we delivered 8% organic sales growth with solid profitability and cash flow. Our performance was strong across all [...]
CARBIOS et Wankai New Materials, filiale du Groupe Zhink, s’engagent pour le déploiement à très grande échelle de la technologie de biorecyclage du PET de CARBIOS en Asie, avec comme première étape la construction d’une usine en Chine.
06/11/2025
Les deux Groupes se sont accordés de manière engageante sur les grands principes de leur collaboration, en vue de déployer une capacité de 1 million de tonnes à long terme, Débutant par la construction en Chine d’une [...]
CARBIOS and Wankai New Materials, a subsidiary of Zhink Group, are committed to the large-scale deployment of CARBIOS’ PET biorecycling technology in Asia, with the first step being the construction of a PET biorecycling plant in China.
06/11/2025
The two Groups have reached a binding agreement on the main principles of their collaboration, with a view to deploying a capacity of one million tonnes in the long term, Starting with the construction of a plant in [...]
Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering
06/11/2025
HAYWARD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines [...]

Pages